Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

被引:16
|
作者
Piccardo, Arnoldo [1 ]
Puntoni, Matteo [2 ]
Ferrarazzo, Giulia [1 ]
Foppiani, Luca [3 ]
Bottoni, Gianluca [1 ]
Altrinetti, Vania [1 ]
Treglia, Giorgio [4 ,5 ]
Naseri, Mehrdad [1 ]
Dib, Bassam [1 ]
Cabria, Manlio [1 ]
Trimboli, Pierpaolo [4 ,5 ]
Massollo, Michela [1 ]
Giovanella, Luca [4 ,5 ]
机构
[1] Galliera Hosp, Nucl Med Dept, Genoa, Italy
[2] Galliera Hosp, Clin Trial Unit, Off Sci Director, Genoa, Italy
[3] Galliera Hosp, Internal Med, Genoa, Italy
[4] Oncol Inst Southern Switzerland, Dept Nucl Med, Bellinzona, Switzerland
[5] Oncol Inst Southern Switzerland, PET CT Ctr, Bellinzona, Switzerland
关键词
Differentiated thyroid cancer; TSH stimulation; Radioactive remnant ablation; Prognosis; STAGING SYSTEM; DTC PATIENTS; RISK; CARCINOMA; THERAPY; MANAGEMENT; GUIDELINES; LEVEL; TSH;
D O I
10.1007/s00259-018-3955-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3-4 weeks before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We aimed to evaluate (1) the reliability of a shorter THW (i.e., 14 days) to achieve adequate TSH levels (i.e., 30 mU/l), (2) the association between length of THW and response to therapy, and (3) the potential association between pre-ablation TSH levels and patients' outcome. Methods After thyroidectomy, all patients started LT4 therapy, which was subsequently discontinued in order to perform RRA. Patients were broken down into two groups according to the length of THW: group A, 2 weeks of THW, and group B, 3-4 weeks of THW. We used clinical, biochemical, and imaging data to evaluate patients' outcome. By means of univariate and multivariate analysis, including main DTC prognostic factors, we assessed the impact of THW length and TSH levels on patients' outcome. Results We evaluated 222 patients, 85 of whom were treated with RRA after a THW period of 2 weeks (group A). All other 137 patients underwent RRA after 3-4 weeks THW (group B). At the time of RRA all patients presented TSH levels >= 30 MU/l After a median follow-up time of 3.4 years, we found 183 patients (82%) with excellent response to treatment and 39 patients (18%) showing incomplete response. Kaplan-Meier response to therapy curves showed that ablation-Tg, tumor size, and lymph node status were significantly associated with prognosis: no associations were found between THW length, TSH levels, and prognosis. Multivariate Cox model showed that only ablation-Tg was significantly associated with treatment response. Conclusions Prior to RRA, a short 2-week THW is an effective method to stimulate TSH levels. No difference in terms of incomplete response to treatment was observed between DTC patients prepared for RRA with a short THW and those with the long THW.
引用
收藏
页码:1218 / 1223
页数:6
相关论文
共 50 条
  • [31] Recombinant TSH or thyroid hormone withdrawal?: A comparison of I-131 remnant ablation rates in thyroid cancer patients
    Luster, M
    Ladenson, P
    Pacini, F
    Schlumberger, M
    Driedger, A
    Kloos, R
    Sherman, S
    Corone, C
    Haugen, B
    Lassmann, M
    Hänscheid, H
    Reiners, C
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S290 - S291
  • [32] Effect of radioiodine therapy under thyroid hormone withdrawal on health-related quality of life in patients with differentiated thyroid cancer
    Ming, Hui
    Yu, Hui
    Liu, Yangbao
    Yang, Lihua
    Chen, Yuanhao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1159 - 1166
  • [33] Success rate of thyroid remnant ablation with a fixed activity of 2 GBq radioiodine in low and high risk patients with differentiated thyroid cancer
    Dunkelmann, S.
    Pawelzig, A.
    Knieling, A.
    Schwarzenboeck, S.
    Schuemichen, C.
    Krause, B. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S348 - S348
  • [34] Average length of hospitalization of patients with differentiated thyroid cancer treated with radioiodine: preparation with thyroid hormone withdrawal versus recombinant thyrotropin
    Montellano Fenoy, A. J.
    Sanchez Catalicio, J.
    Villena Garcia, A. C.
    Perez Angel, F.
    Murcia Durendez, M. J.
    Castellon Sanchez, M. I.
    Gallego Peinado, M.
    Salem, L. M.
    Frutos Esteban, L.
    Navarro Fernandez, J. L.
    Nicolas Ruiz, F.
    Sanz Garcia, D.
    Claver Valderas, M. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S432 - S432
  • [35] Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients
    Verburg, FA
    de Keizer, B
    Lips, CJM
    Zelissen, PMJ
    de Klerk, JMH
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) : 33 - 37
  • [36] The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
    Pak, Kyoungjune
    Cheon, Gi Jeong
    Kang, Keon Wook
    Kim, Seong-Jang
    Kim, In-Joo
    Kim, E. Edmund
    Lee, Dong Soo
    Chung, June-Key
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (06) : 811 - 817
  • [37] Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center
    Tsai, Jia-Ruei
    Wu, Shu-Ting
    Chi, Shun-Yu
    Yang, Yi-Ting
    Chan, Yi-Chia
    Lim, Lay San
    Chiew, Yvonne Ee Wern
    Chen, Wen-Chieh
    Chen, Yung-Nien
    Chou, Chen-Kai
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2023, 39 (02): : 175 - 181
  • [38] Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods
    Casas, Juan Antonio Vallejo
    Mena Bares, Luisa M.
    Galvez, Maria Angeles
    Marlowe, Robert J.
    Romero, Jose M. Latre
    Martinez-Paredes, Maria
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (09) : 840 - 846
  • [39] Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
    Prpic, Marin
    Dabelic, Nina
    Stanicic, Josip
    Jukic, Tomislav
    Milosevic, Milan
    Kusic, Zvonko
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (09) : 744 - 751
  • [40] Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
    Forleo, R.
    Fralassi, N.
    Maino, F.
    Capezzone, M.
    Brilli, L.
    Pilli, T.
    Cantara, S.
    Castagna, M. G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (01) : 139 - 144